Study to evaluate the safety, tolerability and antiretroviral activity of a new therapeutic strategy, based on the administration of dasatinib, an ITK, in patients with recent (3-12 months) asymptomatic HIV-1 infection.
18 to 65 years.
Documented asymptomatic HIV-1 infection of 3-12 months duration (all patients must have a positive Western blot, including the p31 band whose appearance indicates infection of more than 90 days duration).
Not having received ART
CD4 T-lymphocyte count> 350 / μl
Active HBV (HBsAg+ or DNA+) and/or HCV (RNA+) infection in screening.
ALT> 2 UNL, glomerular filtration rate <70 mL / 1.73 m2, leukocytes <4000 / mm3, total lymphocyte count <1000 / mm3, platelets <100,000 / mm3 or Hg <12g / dL.
Pregnancy or active breastfeeding
Ongoing or previous pleural effusion
Eva Bonfill
Lead sponsor
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Sponsor institution